Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;67(3):801-7.
doi: 10.1002/mrm.23065. Epub 2011 Oct 17.

Transient decrease in tumor oxygenation after intravenous administration of pyruvate

Keita Saito  1 , Shingo Matsumoto, Nallathamby Devasahayam, Sankaran Subramanian, Jeeva P Munasinghe, H Douglas Morris, Martin J Lizak, Jan Henrik Ardenkjaer-Larsen, James B Mitchell, Murali C Krishna
Affiliations

Transient decrease in tumor oxygenation after intravenous administration of pyruvate

Keita Saito et al. Magn Reson Med. 2012 Mar.

Abstract

MRI using hyperpolarized (13) C-labeled pyruvate is a promising tool to biochemically profile tumors and monitor their response to therapy. This technique requires injection of pyruvate into tumor-bearing animals. Pyruvate is an endogenous entity but the influence of exogenously injected bolus doses of pyruvate on tumor microenvironment is not well understood. In this study, the effect of injecting a bolus of pyruvate on tumor oxygen status was investigated. EPR oxygen imaging revealed that the partial pressure of oxygen (pO(2)) in squamous cell carcinoma implanted in mice decreased significantly 30 min after [1-(13) C]pyruvate injection, but recovered to preinjection levels after 5 h. Dynamic contrast-enhanced-MRI studies showed that, at the dose of pyruvate used, no changes in tumor perfusion were noticed. Immunohistochemical analysis of hypoxic marker pimonidazole independently verified that the squamous cell carcinoma tumor transiently became more hypoxic by pyruvate injection. Efficacy of radiotherapy was suppressed when X-irradiation was delivered during the period of pyruvate-induced transient hypoxia. These results suggest importance of taking into account the transient decrease in tumor pO(2) after pyruvate injection in hyperpolarized (13) C MRI, because tumor oxygen status is an important factor in determining outcomes of therapies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of tumor pO2 between “with and without” hyperpolarized [1-13C]pyruvate experiments. (A,B) T2 weighted anatomical image of a representative SCC tumor–bearing mouse, and the corresponding pO2 maps. (A) Control tumor which didn't receive [1-13C]pyruvate injection. (B) Tumor measured after hyperpolarized [1-13C]pyruvate experiments. (C) Median pO2 and (D) percentage of the hypoxic region in control tumors (n=5) and tumors after [1-13C]pyruvate experiments (n = 4). There was no significance between control and after 13C-MRI.
Figure 2
Figure 2
Non-invasive monitoring of tumor pO2 by EPRI and effects of pyruvate injection. (A) T2-weighted anatomical image of a representative SCC tumor–bearing mouse, and the corresponding pO2 maps measured before, 30 min, 1 h, and 5 h after [1-13C]pyruvate injection. The adjacent center three slices of the 3D images were displayed, and the every slice has 2 mm thickness. (B) Frequency histogram of the tumor pO2 shown in (A) before (blue) and 30 min after (red) pyruvate injection. (C) Median pO2 in the tumors, and (D) percentage of the hypoxic region (pO2 < 10 mmHg) in the tumors. Each value in (C) and (D) indicates the mean ± SEM of 4 mice. * P<0.01, ** P<0.05, compared with before pyruvate injection.
Figure 3
Figure 3
(A) Immunostaining of hypoxia marker pimonidazole of representative tumors of control mice and pyruvate-treated mice (1 h and 5 h after [1-13C]pyruvate injection). (B) Pimonidazole positive area in control tumors (n = 5) and tumors 1 h after (n=5) and 5 h after (n=5) [1-13C]pyruvate injection.
Figure 4
Figure 4
Tumor perfusion measurements by DCE-MRI. (A) Signal intensity change in T1-weighted images of SCC tumors by Gd-DTPA injection. Gd-DTPA (234.5 mg/kg body weight) was intravenously injected to the mice 2 min after starting the scan. The control mice (n = 4) didn't receive [1-13C]pyruvate injection. The pyruvate group (n = 4) received [1-13C]pyruvate injection 30 min before DCE-MRI. (B) Area under the curves. Each value represents the average of 4 mice and error bars represent SEM. There was no significant difference between the control group and the pyruvate group.
Figure 5
Figure 5
Tumor growth curves after X-irradiation. Control group (●, n = 5) was treated neither X-irradiation nor [1-13C]pyruvate injection. X-irradiations to the tumors were carried out without (■, n = 5), 30 min after (◆, n = 6), and 5 h after (▲, n = 7) [1-13C]pyruvate injection.
See this image and copyright information in PMC

References

    1. Ardenkjær-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc Natl Acad Sci USA. 2003;100:10158–10163. - PMC - PubMed
    1. Golman K, Zandt R, Thaning M. Real-time metabolic imaging. Proc Natl Acad Sci USA. 2006;103:11270–11275. - PMC - PubMed
    1. Kohler SJ, Yen Y, Wolber J, Chen AP, Albers MJ, Bok R, Zhang V, Tropp J, Nelson S, Vigneron DB, Kurhanewicz J, Hurd RE. In vivo 13carbon metabolic imaging at 3T with hyperpolarized 13C-1-pyruvate. Magn Reson Med. 2007;58:65–69. - PubMed
    1. Golman K, Zandt R, Lerche M, Pehrson R, Ardenkjaer-Larsen JH. Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res. 2006;66:10855–10860. - PubMed
    1. Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY, Kohler SJ, Tropp J, Hurd RE, Yen YF, Nelson SJ, Vigneron DB, Kurhanewicz J. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008;68:8607–8615. - PMC - PubMed